Zobrazeno 1 - 10
of 82
pro vyhledávání: ''
Autor:
Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Péter Reményi, Gerard Socié, Gwendolyn van Gorkom, Hélène Labussière-Wallet, Xiao-Jun Huang, Marie Thérèse Rubio, Jenny Byrne, Charles Craddock, Laimonas Griškevičius, Fabio Ciceri, Mohamad Mohty
Publikováno v:
Bone Marrow Transplantation. Nature Publishing Group
We compared transplants (HSCT) from matched related siblings (MSD) with those from matched 10/10 and mismatched 9/10 unrelated (UD) and T-replete haploidentical (Haplo) donors in acute myeloid leukemia (AML) in first complete remission (CR1) achieved
Autor:
Walter J.F.M. van der Velden, Anton F.J. de Haan, Nicole M. A. Blijlevens, Suzanne van Dorp, Jürgen Kuball, Moniek de Witte, Goda Choi, Arnold van der Meer, Gerwin Huls
Publikováno v:
Bone Marrow Transplantation, 56, 2651-2655
Bone Marrow Transplantation, 56, 11, pp. 2651-2655
Bone Marrow Transplantation
Bone marrow transplantation, 56(11), 2651-2655. Nature Publishing Group
Bone Marrow Transplantation, 56, 11, pp. 2651-2655
Bone Marrow Transplantation
Bone marrow transplantation, 56(11), 2651-2655. Nature Publishing Group
Contains fulltext : 241342.pdf (Publisher’s version ) (Closed access) Nonmyeloablative regimens are used for allogeneic hematopoietic cell transplantation (HCT) of older or medically unfit patients, but successful outcome is still hindered by graft
Autor:
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Alexander Kulagin, Hélène Labussière-Wallet, Montserrat Rovira, Didier Blaise, Jan Vydra, Ibrahim Yakoub-Agha, Goda Choi, Péter Reményi, Yener Koc, Jaime Sanz, Fabio Ciceri, Mohamad Mohty
Publikováno v:
Bone marrow transplantation. 58:557-557
Post-transplant cyclophosphamide (PTCy) is being increasingly used as graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) transplanted in first
Autor:
Anton F.J. de Haan, Marco R. de Groot, Nicole N.M. Blijlevens, Gerwin Huls, Andre B. Mulder, Marjan Cruijsen, Nicolaas Schaap, Joop H. Jansen, Edo Vellenga, B. Bär, Frédéric Baron, Walter J.F.M. van der Velden, Jacobien R. Hilberink
Publikováno v:
Bone Marrow Transplantation, 56, 8, pp. 1964-1970
Bone marrow transplantation, 56(8), 1964-1970. Nature Publishing Group
Bone Marrow Transplantation, 56, 1964-1970
Bone marrow transplantation, 56(8), 1964-1970. Nature Publishing Group
Bone Marrow Transplantation, 56, 1964-1970
Contains fulltext : 237746.pdf (Publisher’s version ) (Closed access) Patients with poor risk acute myeloid leukemia (AML) have a dismal outcome. We hypothesized that combining decitabine with a standard non-myeloablative (NMA) conditioning regimen
Autor:
Pavel Jindra, Riita Niittyvuopio, Hervé Tilly, Jakob Passweg, Gesine Bug, Dietrich W. Beelen, Klaus Hirschbühl, Bruno Lioure, Mohamad Mohty, Arnon Nagler, Jan J. Cornelissen, Sebastian Giebel, Hélène Labussière-Wallet, Myriam Labopin, Mohamed Houhou, C. Schmid, Gerald Wulf, Ludovic Gabellier
Publikováno v:
Bone Marrow Transplantation, 56(5), 1190-1199. Nature Publishing Group
Second- and third-generation tyrosine kinase inhibitors (TKI) play an important role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, data on feasibility and efficacy of using these drugs for pers
Autor:
Martin Gramatzki, Dietger Niederwieser, K. Boriskina, Arnon Nagler, Pavel Jindra, Justin Loke, Mohamad Mohty, Jan J. Cornelissen, Arnold Ganser, Charles Craddock, Bipin N. Savani, J Maertens, Didier Blaise, Myriam Labopin, B. Afansayev
Publikováno v:
Bone Marrow Transplantation, 56(3), 614-621. Nature Publishing Group
Patients with acute myeloid leukaemia (AML) who lack a matched sibling or unrelated donor commonly undergo transplantation from a donor matched at 9/10 HLA-A, -B, -C, -DRB1, -DQB1 alleles, and it is unclear if a specific locus mismatch is preferable
Autor:
Ben Carpenter, Montserrat Rovira, Jürgen Kuball, Arnon Nagler, Mohamad Mohty, Sebastian Giebel, Harry C. Schouten, Gérard Socié, Maria H. Gilleece, Myriam Labopin, Jenny Byrne, Zinaida Peric, Ram Malladi, Michael Potter, Christophe Peczynski, Jan J. Cornelissen, Emmanuelle Polge, Nathalie Fegueux
Publikováno v:
Bone Marrow Transplantation, 55(8), 1560-1569. Nature Publishing Group
The optimal reduced-intensity conditioning (RIC) for patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. We retrospectively analyzed 417 patients > 45 years with
Autor:
Dietrich W. Beelen, Arnon Nagler, Riitta Niittyvuopio, Yngvar Fløisand, Mahmoud Aljurf, Jurjen Versluis, Frédéric Baron, Zinaida Peric, Ali Bazarbachi, Charles Craddock, Fabio Ciceri, Anne Huynh, Francesco Lanza, Arnold Ganser, Maria H. Gilleece, Annalisa Ruggeri, Gesine Bug, Eolia Brissot, Norbert Claude Gorin, Mohamad Mohty, Uwe Platzbecker, Jan J. Cornelissen, Myriam Labopin, Florent Malard, J. Sanz, Sebastian Giebel, Didier Blaise, Roni Shouval, Laimonas Griskevicius, Gérard Socié, Jordi Esteve, Noel Milpied, Bipin N. Savani, Christoph Schmid, Alexandros Spyridonidis
Publikováno v:
Bone Marrow Transplantation, 55(6), 1114-1125. Nature Publishing Group
BONE MARROW TRANSPLANTATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
BONE MARROW TRANSPLANTATION
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme we aimed to develop a tool that can capture more standardized the conditioning intensity of allogeneic hematopoietic cell transp
Autor:
Paolo Corradini, Gerald Wulf, Christopher P. Fox, Lutz P. Müller, Nicolaus Kröger, Nadira Duraković, Michel van Gelder, Nicolaas Schaap, Jan J. Cornelissen, Peter Dreger, Mohamad Sobh, Christof Scheid, Hélène Schoemans, Paul Browne, Linda Koster, Jennifer Hoek, Mauricette Michallet, Silvia Montoto, William Krüger, Ariane Boumendil, Wolfgang Bethge, Jakob Passweg, Johannes Schetelig, Domenico Russo
Publikováno v:
Bone Marrow Transplantation, 55, 884-890
Bone Marrow Transplantation, 55(5), 884-890. Nature Publishing Group
Bone Marrow Transplantation, 55, 5, pp. 884-890
Bone Marrow Transplantation, 55(5), 884-890. Nature Publishing Group
Bone Marrow Transplantation, 55, 5, pp. 884-890
Contains fulltext : 220662.pdf (Publisher’s version ) (Closed access) The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%
Publikováno v:
Bone Marrow Transplantation. 55(2):317-324
Allogeneic stem cell transplantation (alloSCT) continues to be the only potentially curative treatment for patients with refractory lymphomas or relapsing after autologous stem cell transplantation. Until recently, alloSCT was restricted to patients